SPRC
Scisparc Ltd
NASDAQ · Pharmaceuticals
$0.68
+0.07 (+11.75%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.37M | 1.35M | 1.33M |
| Net Income | 393.8K | 424.2K | 446.9K |
| EPS | — | — | — |
| Profit Margin | 28.8% | 31.3% | 33.6% |
| Rev Growth | -0.9% | -3.8% | +21.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 742.2K | 970.1K | 740.6K |
| Total Equity | 898.9K | 893.1K | 867.5K |
| D/E Ratio | 0.83 | 1.09 | 0.85 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 809.4K | 830.6K | 717.6K |
| Free Cash Flow | 304.8K | 355.4K | 299.5K |